137 related articles for article (PubMed ID: 37114985)
21. An adaptive multi-stage phase I dose-finding design incorporating continuous efficacy and toxicity data from multiple treatment cycles.
Du Y; Yin J; Sargent DJ; Mandrekar SJ
J Biopharm Stat; 2019; 29(2):271-286. PubMed ID: 30403559
[TBL] [Abstract][Full Text] [Related]
22. Comparison of design methods for a safety run-in phase of a phase II clinical trial.
Ji L; Alonzo TA
Clin Trials; 2023 Apr; 20(2):181-191. PubMed ID: 36628921
[TBL] [Abstract][Full Text] [Related]
23. TITE-BOIN-ET: Time-to-event Bayesian optimal interval design to accelerate dose-finding based on both efficacy and toxicity outcomes.
Takeda K; Morita S; Taguri M
Pharm Stat; 2020 May; 19(3):335-349. PubMed ID: 31829517
[TBL] [Abstract][Full Text] [Related]
24. Improving early phase oncology clinical trial design: The case for finding the optimal biological dose.
Phillips A; Mondal S
Pharm Stat; 2023; 22(4):739-747. PubMed ID: 36669771
[TBL] [Abstract][Full Text] [Related]
25. A hybrid design for dose-finding oncology clinical trials.
Liao JJZ; Zhou F; Zhou H; Petruzzelli L; Hou K; Asatiani E
Int J Cancer; 2022 Nov; 151(9):1602-1610. PubMed ID: 35802470
[TBL] [Abstract][Full Text] [Related]
26. Evaluation of Deviation From Planned Cohort Size and Operating Characteristics of Phase 1 Trials.
Park M; Liu S; Yap TA; Yuan Y
JAMA Netw Open; 2021 Feb; 4(2):e2037563. PubMed ID: 33595664
[TBL] [Abstract][Full Text] [Related]
27. Design considerations for phase I/II dose finding clinical trials in Immuno-oncology and cell therapy.
Liu R; Lin J; Li P
Contemp Clin Trials; 2020 Sep; 96():106083. PubMed ID: 32659438
[TBL] [Abstract][Full Text] [Related]
28. [Introduction of Oncology Dose-Finding Trial Designs].
Takeda K
Gan To Kagaku Ryoho; 2022 Apr; 49(4):365-370. PubMed ID: 35444116
[TBL] [Abstract][Full Text] [Related]
29. A Bayesian design for finding optimal biological dose with mixed types of responses of toxicity and efficacy.
Zhang D; Xu J
Contemp Clin Trials; 2023 Apr; 127():107113. PubMed ID: 36758934
[TBL] [Abstract][Full Text] [Related]
30. Adaptive Cohort Size Determination Method for Bayesian Optimal Interval Phase I/II Design to Shorten Clinical Trial Duration.
Kojima M
JCO Precis Oncol; 2023 Jul; 7():e2300087. PubMed ID: 37487148
[TBL] [Abstract][Full Text] [Related]
31. Comparison Between Simultaneous and Sequential Utilization of Safety and Efficacy for Optimal Dose Determination in Bayesian Model-Assisted Designs.
Li R; Takeda K; Rong A
Ther Innov Regul Sci; 2023 Jul; 57(4):728-736. PubMed ID: 37087525
[TBL] [Abstract][Full Text] [Related]
32. Incorporating historical information to improve phase I clinical trials.
Zhou Y; Lee JJ; Wang S; Bailey S; Yuan Y
Pharm Stat; 2021 Nov; 20(6):1017-1034. PubMed ID: 33793044
[TBL] [Abstract][Full Text] [Related]
33. Comparative review of novel model-assisted designs for phase I clinical trials.
Zhou H; Murray TA; Pan H; Yuan Y
Stat Med; 2018 Jun; 37(14):2208-2222. PubMed ID: 29682777
[TBL] [Abstract][Full Text] [Related]
34. TITE-gBOIN-ET: Time-to-event generalized Bayesian optimal interval design to accelerate dose-finding accounting for ordinal graded efficacy and toxicity outcomes.
Takeda K; Yamaguchi Y; Taguri M; Morita S
Biom J; 2023 Oct; 65(7):e2200265. PubMed ID: 37309248
[TBL] [Abstract][Full Text] [Related]
35. A robust two-stage design identifying the optimal biological dose for phase I/II clinical trials.
Zang Y; Lee JJ
Stat Med; 2017 Jan; 36(1):27-42. PubMed ID: 27538818
[TBL] [Abstract][Full Text] [Related]
36. Probability intervals of toxicity and efficacy design for dose-finding clinical trials in oncology.
Lin X; Ji Y
Stat Methods Med Res; 2021 Mar; 30(3):843-856. PubMed ID: 33327870
[TBL] [Abstract][Full Text] [Related]
37. BOIN-ETC: A Bayesian optimal interval design considering efficacy and toxicity to identify the optimal dose combinations.
Kakizume T; Takeda K; Taguri M; Morita S
Stat Methods Med Res; 2024 Apr; 33(4):716-727. PubMed ID: 38444354
[TBL] [Abstract][Full Text] [Related]
38. Dose escalation with over-dose and under-dose controls in Phase I/II clinical trials.
Chen Z; Yuan Y; Li Z; Kutner M; Owonikoko T; Curran WJ; Khuri F; Kowalski J
Contemp Clin Trials; 2015 Jul; 43():133-41. PubMed ID: 26012358
[TBL] [Abstract][Full Text] [Related]
39. A comparison of phase I dose-finding designs in clinical trials with monotonicity assumption violation.
Abbas R; Rossoni C; Jaki T; Paoletti X; Mozgunov P
Clin Trials; 2020 Oct; 17(5):522-534. PubMed ID: 32631095
[TBL] [Abstract][Full Text] [Related]
40. TITE-gBOIN: Time-to-event Bayesian optimal interval design to accelerate dose-finding accounting for toxicity grades.
Takeda K; Xia Q; Liu S; Rong A
Pharm Stat; 2022 Mar; 21(2):496-506. PubMed ID: 34862715
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]